Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 1;4(2):e2037120.
doi: 10.1001/jamanetworkopen.2020.37120.

Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy

Affiliations

Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy

Kartik Sehgal et al. JAMA Netw Open. .

Abstract

Importance: Despite approximately 40% of patients having Eastern Cooperative Oncology Group (ECOG) performance status (PS) scores of at least 2 in the real world, most landmark clinical trials that led to the use of pembrolizumab as standard of care in advanced non-small cell lung cancer (NSCLC) excluded this group.

Objective: To evaluate whether an ECOG PS score of at least 2 at the start of therapy is associated with progression-free survival (PFS) and overall survival (OS) in advanced NSCLC treated with pembrolizumab monotherapy.

Design, setting, and participants: This cohort study included all consecutive patients with advanced NSCLC who underwent treatment with palliative pembrolizumab monotherapy from February 2016 to October 2019 at a single academic cancer center, with data censoring on January 15, 2020.

Exposures: ECOG PS score at start of therapy, with 0 and 1 indicating fully active or restricted in strenuous activity and scores of 2 and higher indicating increasing disability.

Main outcomes and measures: PFS and OS, measured from initiation of pembrolizumab monotherapy.

Results: Of 74 patients (median [range] age, 68.5 [33-87] years; 36 [48.7%] women; 53 [71.6%] White individuals) with median follow-up of 19.5 (95% CI, 13.4-27.8) months, 45 (60.8%) had an ECOG PS of 0 or 1, while 29 (39.2%) had an ECOG PS of at least 2. There were no significant differences in the baseline characteristics, except in age. Compared with patients with PS scores of 0 or 1, those with PS scores of at least 2 had significantly lower disease control rates (38 [88.4%] vs 15 [53.6%]; P = .002), shorter median PFS (7.9 [95% CI, 4.6-15.4] months vs 2.3 [95% CI, 1.8-4.8] months; P = .004), and shorter median OS (23.2 [14.0 vs 35.7] months vs 4.1 [95% CI, 2.1-6.9] months; P < .001). Among those potentially eligible for subsequent cancer-directed therapy beyond pembrolizumab monotherapy, patients in the group with PS scores of at least 2 were less likely to receive it than those with PS scores of 0 or 1 (2 [8.3%] vs 14 [45.2%]; P = .003). Multivariable adjustment for baseline characteristics confirmed ECOG PS of at least 2 as an independent risk factor for worse PFS (HR, 2.02; 95% CI, 1.09-3.74; P = .03) and worse OS (HR, 2.87; 95% CI, 1.40-5.89; P = .004).

Conclusions and relevance: In this cohort study, having an ECOG PS score of at least 2 was associated with poorer prognosis for treatment of advanced NSCLC with palliative pembrolizumab monotherapy. Further prospective studies are needed to evaluate more objective and consistent measures of functional status to facilitate identification of patients with borderline performance status who may achieve durable clinical benefit from treatment with pembrolizumab monotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Rangachari reported receiving personal fees from Advance Medical Expert, DynaMed, and AstraZeneca and receiving institutional research support from Abbvie/Stemcentrx, Novocure, and Bristol Myers Squibb outside the submitted work. Dr Costa reported receiving personal fees from Takeda/Millennium Pharmaceuticals, AstraZeneca, Pfizer, BluePrint Medicin, and TelaDoc and receiving institutional support from Merck Sharp and Dohme, Merrimack Pharmaceuticals, Bristol Myers Squibb, Clovis Oncology, Spectrum Pharmaceuticals, and Tesaro outside the submitted work. Dr Shea reported receiving institutional research support from Bristol Myers Squibb, Clovis Oncology, Pfizer, and Eli Lilly and Co outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Treatment Response by Performance Status
A, B, Black dots represent treatment before confirmed progression of disease. Other dots represent treatment beyond progression, with individual patients represented by unique colors. Arrows represent ongoing treatment. ECOG indicates Eastern Cooperative Oncology Group.
Figure 2.
Figure 2.. Outcomes by Performance Status
ECOG indicates Eastern Cooperative Oncology Group.

Similar articles

Cited by

References

    1. Passaro A, Spitaleri G, Gyawali B, de Marinis F. Immunotherapy in non-small-cell lung cancer patients with performance status 2: clinical decision making with scant evidence. J Clin Oncol. 2019;37(22):1863-1867. doi:10.1200/JCO.18.02118 - DOI - PubMed
    1. Lilenbaum RC, Cashy J, Hensing TA, Young S, Cella D. Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol. 2008;3(2):125-129. doi:10.1097/JTO.0b013e3181622c17 - DOI - PubMed
    1. Alessi JV, Awad MM. Immunotherapy in lung cancer: effective for patients with poor performance status? Lancet Respir Med. 2020;8(9):838-839. doi:10.1016/S2213-2600(20)30107-7 - DOI - PubMed
    1. Reck M, Rodríguez-Abreu D, Robinson AG, et al. ; KEYNOTE-024 Investigators . Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823-1833. doi:10.1056/NEJMoa1606774 - DOI - PubMed
    1. Marur S, Singh H, Mishra-Kalyani P, et al. . FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies. Semin Oncol. 2018;45(4):220-225. doi:10.1053/j.seminoncol.2018.08.007 - DOI - PubMed

Publication types

MeSH terms

Substances